Actuate Therapeutics, Inc. Common stock (ACTU) Stock Analysis
Actuate Therapeutics offers asymmetric upside from elraglusib’s Phase 2-validated pancreatic-cancer signal, but near-term survival depends on financing, severe dilution and Nasdaq compliance.
Overview
Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage, pre-revenue biotech focused on elraglusib, a first-in-class GSK-3β inhibitor being developed for pancreatic and other difficult-to-treat cancers. Its randomized Phase 2 mPDAC trial provides the central investment evidence: elraglusib plus gemcitabine/nab-paclitaxel produced median overall survival of 10.1 months versus 7.2 months for chemotherapy alone (HR 0.62; p=0.02), and 24-month survival of 12.9% versus 2.6%. The pipeline also includes salivary gland carcinoma, pediatric neuroblastoma, and an oral formulation for solid tumors and RAS-inhibitor combinations. **The clinical upside is substantial, but Actuate has no product revenue and depends on financing to reach pivotal trials.** Q2 2026 revenue was $0; net loss was $4.87 million. Cash of $4.43 million at June 30, 2026 led management to disclose substantial doubt about funding operations past September. A proposed 50 million-share offering at $0.819 risks severe dilution, while Nasdaq compliance is due by January 11, 2027. The report’s probability-weighted five-year target is $10.88 versus a $0.819 baseline, but labels the investment highly speculative. Near-term catalysts are offering execution, Phase 3 protocol and trial progress, and listing compliance.